Key result
Tinzaparin is a low-molecular-weight heparin that is at least as safe and effective as unfractionated heparin for the treatment of deep-vein thrombosis.
Why the study?
Does tinzaparin sodium safely and effectively treat acute symptomatic deep-vein thrombosis compared to unfractionated heparin?
Population
Patients with acute symptomatic deep-vein thrombosis (DVT) with or without pulmonary embolism (PE)
Comparison
Tinzaparin sodium vs Unfractionated heparin (UFH)
Design
Review
Authors
Loading...
May guide LMWH selection for DVT; leaves open prospective trials versus DOACs.
Does tinzaparin sodium safely and effectively treat acute symptomatic deep-vein thrombosis compared to unfractionated heparin?
Tinzaparin is an effective and safe low-molecular-weight heparin for the treatment of acute symptomatic DVT with or without PE, offering improved pharmacokinetics over unfractionated heparin.
Neely et al. (2002) conducted a review in Deep-vein thrombosis (DVT) with or without pulmonary embolism (PE). Tinzaparin sodium vs. Unfractionated heparin (UFH) was evaluated. Tinzaparin is a low-molecular-weight heparin that is at least as safe and effective as unfractionated heparin for the treatment of deep-vein thrombosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: